Bluebird bio — ASH 2018
55 slides from Bluebird bio's conference presentation, Dec 4, 2018
Slide 1: ASH 2018
ASH 2018 December 3, 2018 NASDAQ: BLUE Exhibit 99.1 Exhibit 99.1 ASH 2018 December 3, 2018 NASDAQ: BLUE
Slide 2: Forward-Looking Statements
These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expre
Slide 3: Agenda
Agenda Liz Pingpank, director, investor relations, bluebird bio Nick Leschly, chief bluebird, bluebird bio David Davidson, M.D., chief medical officer, bluebird bio John Tisdale, M.D., National Heart, Lung and Blood Institute at the National Institutes of Health (NIH), Bethesda, MD Liviu Niculescu,
Slide 4: Welcome
Welcome Nick Leschly, chief bluebird Welcome Nick Leschly, chief bluebird
Slide 5: Making Hope A Reality
Making Hope A Reality Making Hope A Reality
Slide 6: The Gene Therapy Products Company
T H E G E N E T H E R A P Y P R O D U C T S C O M P A N Y LentiGlobin SCD Data-Driven Acceleration LentiGlobin TDT Potential First Approval (2019) Lenti-D CALD Potential First Approval (2020) bb2121 Multiple Myeloma Potential First Approval (2020) Products on the Market 2+ Additional Programs in the
Slide 7: 2018 – A Year of Tremendous Learning and Growth
2018 – A Year of Tremendous Learning and Growth First Marketing Authorization Application (MAA) filed with EMA with PRIME Designation 2019 EU launch on track U.S. registration plan based on Northstar-2 with Breakthrough Designation Transfusion-Dependent β-Thalassemia Robust and consistent production
Slide 8: Breadth & Depth of ASH Data Underscores BLUE Potential
Breadth & Depth of ASH Data Underscores BLUE Potential HGB-206 Group C: Updated results HGB-206 Group A & B: Updated results Real world evidence: U.S. population HGB-205: Analysis of RBC properties in patients LentiGlobin SCD First look: CRB-402 initial results in R/R multiple myeloma bb21217 MM BCL
Slide 9: Transfusion-Dependent β-Thalassemia and Sickle Cell Disease
Transfusion-Dependent β-Thalassemia and Sickle Cell Disease David Davidson, M.D., chief medical officer, bluebird bio Transfusion-Dependent β-Thalassemia and Sickle Cell Disease David Davidson, M.D., chief medical officer, bluebird bio Nasdaq 9
Slide 10: Transfusion-Dependent β-Thalassemia (TDT)
Transfusion-Dependent β-Thalassemia (TDT) Inherited blood disease that requires lifelong, frequent blood transfusions and iron reduction therapy PROGRAM OVERVIEW Filed MAA with European Medicines Agency General regulatory agreement with FDA for BLA filing Studies ongoing: Northstar-2 (HGB-207) North
Slide 11: 8/10 Patients with Non-β0/β0 Genotypes Free from Chronic RBC Transfusions
8/10 Patients with Non-β0/β0 Genotypes and 3/8 Patients with β0/β0 Genotypes are Free from Chronic RBC Transfusions 11.1 10.4 12.0 12.5 14.1 9.7 9.9 10.3 Time from treatment to last transfusion Time from last transfusion to last follow-up 9.1 10.3 10.9 Hb (g/dL) At last study visit Months Post Drug
Slide 12: 10/11 Patients Are Transfusion Free with Hemoglobin >11g/dL
10/11 Patients Are Transfusion Free with Hemoglobin >11g/dL *Male patients; ‡Hb supported by transfusions; †Weighted average Hb ≥9 g/dL without any RBC transfusions for ≥12 months; Hb, hemoglobin; VCN, vector copy number (vector copies/diploid genome) Data as of September 14, 2018 Time free from chr
Slide 13: High Levels of Gene Therapy Derived HbAT87Q in 10/11 Patients
High Levels of Gene Therapy Derived HbAT87Q in 10/11 Patients *Male patients; ‡Patient is homozygous for IVS-I-5 β-globin mutation; ^Patient is heterozygous for IVS-I-5 β-globin mutation. Hb, hemoglobin. Transfused Data as of September 14, 2018 Transfused High Levels of Gene Therapy Derived HbAT87Q
Slide 14: Normal Total Hemoglobin in First Northstar-3 β0/β0 Patient
Normal Total Hemoglobin in First Northstar-3 β0/β0 Patient Data as of September 14, 2018 unless otherwise noted *Includes investigator reported data as of November 19, 2018, not from programmed statistical outputs AEs, adverse events; DP, drug product; Hb, hemoglobin; VCN, vector copy number (vector
Slide 15: TDT Data – Key Takeaways
TDT Data – Key Takeaways bb2121: KarMMa enrollment complete; clinical program is advancing including planned 2019 studies in front line, in collaboration with Celgene bb21217: Overall response rate of 83% at first dose level tested (vs. 57% at same dose in CRB-401); early indications of increased pe
Slide 16: Sickle Cell Disease Development Plan
Sickle Cell Disease Development Plan Sickle Cell Disease Development Plan Nasdaq Blue 16
Slide 17: Sickle Cell Disease (SCD)
Sickle Cell Disease (SCD) Severe blood disorder that causes anemia, frequent pain crises and shortened lifespan Global annual birth incidence ~ 300,000 – 400,000 Mean age of death in the U.S. is 44 years1 PROGRAM OVERVIEW Plan to pursue accelerated development path based on hematological primary end
Slide 18: Increasing Momentum to #ConquerSCD
Increasing Momentum to #ConquerSCD “Unfortunately, some treated [SCD] patients will have no reduction of their symptoms and the disease will continue to progress,” says Ann T. Farrell, M.D., director of the FDA’s Division of Hematology Products, CDER. “Better therapies are desperately needed,” Farre
Slide 19: Accelerated Development Plan Using Novel Composite Primary Endpoint
Ongoing Phase 1/2, single arm, multi-center, U.S. study N=41 (Group C) Primary Endpoint: HbAT87Q and Total Hb Key Secondary Endpoint: Reduction in severe VOEs ≥12 years of age - ≤50 years of age Phase 1/2, single-center in France N=7 (4 β-thalassemia) HGB-205 (Transfusion-dependent b-thalassemia & s
Slide 20: Sickle Cell Disease
Sickle Cell Disease John Tisdale, M.D., National Heart, Lung and Blood Institute at the NIH, Bethesda, MD Sickle Cell Disease John Tisdale, M.D., National Heart, Lung and Blood Institute at the NIH, Bethesda, MD Nasdaq Blue 20
Slide 21: Evolution of LentiGlobin in SCD
Evolution of LentiGlobin in SCD Peripheral Blood Modified Protocol and Refined Manufacturing Process Group C High High High Yes Transfusions (Pre-Treatment) Conditioning Total Cell Dose Transduction (VCN & % Transduced) Planned Cell Source Shift Cell Source: Apheresis Cell Source: Bone Marrow High C
Slide 22: Group C: Patient Characteristics
Group C: Patient Characteristics N=14 Patients Who Started Cell Collection Parameter Group C N=14 Age at consent median (min – max), years 25.5 (18 – 36) Gender 6 F 8 M Genotype βS/βS 14 Prior SCD History Hydroxyurea use, n 8 Recurrent VOCs*, n Annualized no. of events, median (min – max) 9 6.5 (3.5
Slide 23: Group C: Safety Profile
Group C: Safety Profile Generally Consistent with Myeloablative Busulfan Conditioning Data as of September 14, 2018 Non-hematologic* grade ≥ 3 AEs Post-DP infusion in ≥2 patient n (%) N=9 Febrile neutropenia 6 (67) Stomatitis 6 (67) Serious AEs* Post-DP infusion in ≥1 patient n (%) N=9 Abdominal pai
Slide 24: Critical Elements of LentiGlobin Success in SCD
Critical Elements of LentiGlobin Success in SCD Fundamentally Improving Red Blood Cell Physiology 4 out of 4 patients with ≥47% anti-sickling Hb (range: 47% - 62%) at 6 months Sustained expression of HbAT87Q levels through 9 months follow-up High & Stable Levels of HbAT87Q Derived Hemoglobin & Total
Slide 25: Critical Elements of LentiGlobin Success in SCD
Critical Elements of LentiGlobin Success in SCD Fundamentally Improving Red Blood Cell Physiology 4 out of 4 patients with ≥47% anti-sickling Hb (range: 47% - 62%) at 6 months Sustained expression of HbAT87Q levels through 9 months follow-up High & Stable Levels of HbAT87Q Derived Hemoglobin & Total
Slide 26: Group C: Stable Peripheral Blood VCN, HbAT87Q Trajectory
Group C: Stable Peripheral Blood VCN, HbAT87Q Trajectory Robust and Consistent Data as of September 14, 2018 For Group A patients, medians (Q1, Q3) depicted; Group A patients with month 36 study visit (N=2) Group C: Stable Peripheral Blood VCN, HbAT87Q Trajectory Robust and Consistent For Group A pa
Slide 27: Group C Patients Achieving Sickle Trait-like Hemoglobin Distribution
Group C Patients Achieving Sickle Trait-like Hemoglobin Distribution Data as of September 14, 2018 βS-globin decreasing with increasing HbAT87Q (average concentration of hemoglobin per cell has not changed post-treatment) Increase in βA-T87Q Results in Decrease in βS βS βA -T87Q βS Pre-Infusion Post
Slide 28: Critical Elements of LentiGlobin Success in SCD
Critical Elements of LentiGlobin Success in SCD Fundamentally Improving Red Blood Cell Physiology 4 out of 4 patients with ≥47% anti-sickling Hgb (range: 47% - 62%) at 6 months Sustained expression of HbAT87Q levels through 9 months follow up High & Stable Levels of HbAT87Q Derived Hemoglobin & Tota
Slide 29: Impact on Clinical Outcomes of SCD in Group C
Impact on Clinical Outcomes of SCD in Group C Normalization of Key Biomarkers of Hemolysis Over Time Reticulocyte Counts Lactate Dehydrogenase Median (Q1, Q3) depicted Dot-dash lines denote lower and upper limits of normal values Data as of September 14, 2018 Total Bilirubin Impact on Clinical Outco
Slide 30: Critical Elements of LentiGlobin Success in SCD
Critical Elements of LentiGlobin Success in SCD Fundamentally Improving Red Blood Cell Physiology 4 out of 4 patients with ≥47% anti-sickling Hgb (range: 47% - 62%) at 6 months Sustained expression of HbAT87Q levels through 9 months follow up High & Stable Levels of HbAT87Q Derived Hemoglobin & Tota
Slide 31: LentiGlobin has Anti-Sickling Activity Comparable to Sickle Trait
Healthy Donor [AA] (n = 4) Sickle Trait [AS] (n = 12) Sickle Cell [SS] (n = 6) Hereditary Persistence of Fetal Hemoglobin with SS (n = 4)* *HbF levels in HPFH donors ranged from 28.1 to 42.3% Subject 206-114-1315 PB at 9 months post-infusion LentiGlobin has Anti-Sickling Activity Comparable to Sickl
Slide 32: Two Independent Assays Indicate Near Pancellular βA-T87Q Distribution
Two Independent Assays Indicate Near Pancellular βA-T87Q Distribution Majority of Patient RBCs are Positive for Anti-Sickling Globin βS Healthy Donor (A/A) βS Sickle Cell Disease (S/S) βS βA or βA-T87Q 100% 100% A/S 100% Sickle Trait (A/S) βA or βA-T87Q βA or βA-T87Q Two Independent Assays Indicate
Slide 33: Two Independent Assays Reveal Near Pancellular βA-T87Q Distribution
Two Independent Assays Reveal Near Pancellular βA-T87Q Distribution Majority of Patient RBCs are Positive for Anti-Sickling Globin 8.6% 91.4% Subject 1315 M9 Single Cell Western Subject 1315 M9 Flow Cytometry βS Healthy Donor (A/A) βS Sickle Cell Disease (S/S) βS βA or βA-T87Q 100% 100% A/S 100% Sic
Slide 34: Critical Elements of LentiGlobin Success in SCD
Critical Elements of LentiGlobin Success in SCD Fundamentally Improving Red Blood Cell Physiology 4 out of 4 patients with ≥47% anti-sickling Hgb (range: 47% - 62%) at 6 months Sustained expression of HbAT87Q levels through 9 months follow up High & Stable Levels of HbAT87Q Derived Hemoglobin & Tota
Slide 35: Impact on Clinical Outcomes of SCD
Impact on Clinical Outcomes of SCD Resolution of Anemia (and Robust HbAT87Q Levels) in All Patients by 6 Months; No VOEs Since DP Infusion Data as of September 14, 2018 * Denotes female patients; ╪ Patient current receiving phlebotomy Group C: All patients free of VOEs as of data cut-off Impact on C
Slide 36: Critical Elements of LentiGlobin Success in SCD
Critical Elements of LentiGlobin Success in SCD Fundamentally Improving Red Blood Cell Physiology 4 out of 4 patients with ≥47% anti-sickling Hb (range: 47% - 62%) at 6 months Sustained expression of HbAT87Q levels through 9 months follow-up High & Stable Levels of HbAT87Q Derived Hemoglobin & Total
Slide 37: SCD Data – Key Takeaways
SCD Data – Key Takeaways bb2121: KarMMa enrollment complete; clinical program is advancing including planned 2019 studies in front line, in collaboration with Celgene bb21217: Overall response rate of 83% at first dose level tested (vs. 57% at same dose in CRB-401); early indications of increased pe
Slide 38: Multiple Myeloma
Multiple Myeloma Liviu Niculescu, M.D., Ph.D., SVP, global medical affairs, bluebird bio Multiple Myeloma Liviu Niculescu, M.D., Ph.D., SVP, global medical affairs, bluebird bio
Slide 39: Multiple Myeloma
Multiple Myeloma A lethal blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems and bone fractures BCMA PROGRAM OVERVIEW bb2121: Enrollment in KarMMa registration-enabling study complete (N=140) Additional studies advancing: KarMMa-2 in 2nd line Phase 2
Slide 40: CRB-401 Data at ASCO 2018 - Tumor Response and PFS
CR, complete response; mDOR, median duration of response; ORR, objective response rate; PD, progressive disease; PR, partial response; sCR, stringent CR; VGPR, very good partial response. Data cut-off: March 29, 2018. 1Patients with ≥2 months of response data or PD/death within <2 months. ORR is def
Slide 41: Advancing bb2121 into Earlier Lines of Multiple Myeloma
Advancing bb2121 into Earlier Lines of Multiple Myeloma Multiple Myeloma Trials planned in 2019 KarMMa 3 (MM-003) KarMMa 2 (MM-002) KarMMa (MM-001) Phase 3 Phase 2 Phase 1 Registration-enabling trial in late line enrollment complete Front line setting Phase 2 studies planned in 2019 3rd line+ Phase
Slide 42: Multiple Myeloma: bb21217
Multiple Myeloma: bb21217 Nina Shah, M.D., University of California, San Francisco Multiple Myeloma: bb21217 Nina Shah, M.D., University of California, San Francisco
Slide 43: Increasing Long-lived, Memory-like T Cell Subsets Hypothesis
Hypothesis: Increasing long-lived, memory-like T Cell subsets in the drug product may result in enhanced persistence of functional anti-BCMA CAR T cells in vivo TN Cell TSCM Cell TCM Cell TEM Cell TEFF Cell T Cell Plasticity Self Renewal Long-lived Terminally Differentiated No Self Renewal Short-liv
Slide 44: Preclinical Models: bb21217 is Enriched for Memory-like T Cells
Preclinical Models: bb21217 is Enriched for Memory-like T Cells Exhibits; Enhanced Persistence of Anti-tumor Effect CD62L and CD27 are markers of memory-like T cells bb21217 is significantly enriched for T cells with this memory-like phenotype bb007 enhances anti-tumor effect in mouse models ONLY CA
Slide 45: CRB-402 Study Design and Status
CRB-402 Phase 1 Study Design and Status 3 + 3 dose escalationa 300 × 106 450 × 106 800 × 106 150 × 106 Collected N=13 Dosed N=12 (150 × 106 dose) HTBb n=6LTBb n=6 Study Status as of Oct 18, 2018 Median (min, max) follow-up 26 wk (4, 51) Primary endpoints: AEs, DLTs Other endpoints: Responsec, PFS, O
Slide 46: Early Clinical Safety and Tolerability Consistent with CAR T Experience
Early Clinical Safety and Tolerability Consistent with CAR T Experience CRS occurred in 67% of patients Mostly grade 1/2, 1 grade 3, no grade 4 Median time to onset of CRS 4.5 days (2,11) Manageable with or without tocilizumab 1 patient experienced DLT (grade 4 encephalopathy and grade 3 CRS) Patien
Slide 47: Clinical Data is Early But Consistent with Goal of Enhanced Persistence
Clinical Data is Early But Consistent with Goal of Enhanced Persistence Robust and reliable bb21217 CAR T cell expansion post-infusion observed at first dose Early bb21217 clinical data is consistent with robust functional CAR T cell persistence Enrichment for memory-like CAR T cells observed in pre
Slide 48: Clinical Responses Observed in 10/12 Patients at First Dose Level
Clinical Responses Observed in 10/12 Patients (83%) at First Dose Level Tested (150 x 106 CAR+ T cells) Data as of October 18, 2018 b b a Clinical Responses Over Time CR, complete response; MRD, minimal residual disease; PR, partial response; VGPR, very good partial response. *Patients with high tum
Slide 49: High Clinical Response Rate Observed at First Dose Level
High Clinical Response Rate Observed at First Dose Level (150 x 106 CAR+ T cells) Clinical Response bb21217-Treated (N=12) ORR,a n (%) [95% CI] 10 (83.3) [51.6, 97.9] sCR/CR 3 (25) ≥VGPR 6 (50) MRD status in bone marrow, n MRD-evaluable respondersb 4 MRD-neg 4c Median time to first response (min, ma
Slide 50: Promising Early Data with Next-Generation Anti-BCMA CAR T
Promising Early Data with Next-Generation Anti-BCMA CAR T bb21217 demonstrated promising early clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma at first dose level tested 83% ORR with 90% of responses ongoing Elimination of MRD in the bone marrow of all 4 ev
Slide 51: BCMA Data – Key Takeaways
BCMA Data – Key Takeaways bb2121: KarMMa enrollment complete; clinical program is advancing including planned 2019 studies in front line, in collaboration with Celgene bb21217: Overall response rate of 83% at first dose level tested (vs. 57% at same dose in CRB-401); early indications of increased p
Slide 52: ASH Highlights: Next Generation Programs / Platforms
ASH Highlights: Next Generation Programs / Platforms First clinical demonstration of the potential to genetically manipulate HbF levels through BCL11a Novel LVV expressing a shRNAmiR to knock down BCL11a at the level exclusively in erythroid cells Robust knock down of BCL11a observed in patient cell
Slide 53: Ending 2018 Strong: Key Milestones Achieved
Ending 2018 Strong: Key Milestones Achieved TDT SCD MM CALD Pivotal Registration Plans Update Northstar-3 (HGB-212) Early Data MAA Filing in Non-β0/β0 Genotypes Earlier Line Studies Advancing* CRB-402 bb21217 Early Data Northstar-2 (HGB-207) Updated Data HGB-206 Data CRB-401 bb2121 Updated Data Star
Slide 54: bluebirdbio
bluebirdbio’
Slide 55: ASH Data – Key Takeaways
ASH Data – Key Takeaways bb2121: KarMMa enrollment complete; clinical program is advancing including planned 2019 studies in front line, in collaboration with Celgene bb21217: Overall response rate of 83% at first dose level tested (vs. 57% at same dose in CRB-401); early indications of increased pe